Serum iron and iron stores in non-anemic patients with fibromyalgia |
| |
Authors: | Mader Reuven Koton Yael Buskila Dan Herer Paula Elias Mazen |
| |
Institution: | (1) Rheumatic Diseases Unit, Ha’Emek Medical Center, Afula, 18101, Israel;(2) Department of Medicine D, Ha’Emek Medical Center, Afula, 18101, Israel;(3) Department of Medicine, Soroka Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel;(4) Ha’Emek Medical Center, Afula, Israel;(5) Department of Medicine C, Ha’Emek Medical Center, Afula, 18101, Israel;(6) Technion Institute of Technology, Haifa, Israel |
| |
Abstract: | The aim of the study was to assess iron serum levels and markers of iron stores in non-anemic fibromyalgia (FM) patients and
to evaluate their impact on the prevalence and clinical manifestations of FM patients. Eighty-four patients with primary FM
and 87 controls were investigated. Demographic and clinical data were collected from all participants. All patients completed
the fibromyalgia impact questionnaire (FIQ). Patients evaluated the effect of the disease on their daily activity (DA) and
judged the severity (DS) of the disease on a 0–10 scale. Venous blood was tested for serum iron, transferrin, ferritin, and
soluble transferrin receptors (sTfR). Iron deficiency was defined if any of the following were present: serum iron <40 μg/dL,
serum ferritin levels <10 ng/mL, or sTfR levels >28.1 nmol/L. Analysis at a cutoff level of serum ferritin levels ≤30 ng/mL
and sTfR/ferritin ratio was also performed. Hemoglobin, iron, transferrin, sTfR, ferritin levels, and sTfR/ferritin ratios
did not differ between the groups. The mean FIQ score was 57.13 ± 20.21 and the DA and DS scores were 6.79 ± 2.97 and 6.74 ± 3.09,
respectively. No correlations were found between the parameters studied and the FIQ or its ten individual items. Thirty-eight
controls (43.7%) and 23 FM patients (27.4%) had ferritin levels of ≤30 (p < 0.04). Within the FM group, lower levels were associated with lower total FIQ score and FIQ subscale scores. Patients with
FM do not have reduced serum levels of iron or surrogate markers of iron stores. At present, there is no evidence to support
iron supplementation in the treatment of FM. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|